TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

TCG Crossover Management LLC cut its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 550,000 shares of the company's stock after selling 329,344 shares during the quarter. TCG Crossover Management LLC owned approximately 1.36% of Keros Therapeutics worth $8,706,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of KROS. Darwin Global Management Ltd. increased its holdings in Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after purchasing an additional 163,403 shares during the period. Emerald Mutual Fund Advisers Trust grew its position in shares of Keros Therapeutics by 37.9% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 155,347 shares of the company's stock worth $2,459,000 after buying an additional 42,734 shares in the last quarter. Northern Trust Corp increased its stake in shares of Keros Therapeutics by 11.3% during the fourth quarter. Northern Trust Corp now owns 296,467 shares of the company's stock valued at $4,693,000 after buying an additional 30,111 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Keros Therapeutics by 140.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 40,356 shares of the company's stock valued at $639,000 after acquiring an additional 23,550 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in Keros Therapeutics in the fourth quarter worth about $8,612,000. Institutional investors own 71.56% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on KROS. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research report on Thursday, January 16th. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Truist Financial decreased their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, Oppenheimer reduced their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $40.33.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This represents a 27.01 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.90% of the stock is currently owned by company insiders.

Keros Therapeutics Stock Up 0.5 %

Shares of Keros Therapeutics stock traded up $0.08 during midday trading on Friday, hitting $14.65. The company had a trading volume of 651,753 shares, compared to its average volume of 810,507. The company has a fifty day simple moving average of $11.92 and a 200 day simple moving average of $26.32. The stock has a market cap of $594.95 million, a price-to-earnings ratio of -2.81 and a beta of 1.39. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.